ClinicalTrials.gg

Program

HS_SW01 cells injection

Its studies are mostly in Primary Ovarian Insufficiency · Scleroderma, Systemic · Spondylitis, Ankylosing, led by Shenzhen Huishan Biotechnology.

Furthest: phase 2, since Apr 8, 20263 company-led studies, 3 open or runningNext primary completion: Dec 31, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Shenzhen Huishan Biotechnology33 open or runningphase 2since Apr 8, 2026Apr 8, 2026Dec 31, 2027phase 2 · NCT07551895

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Apr 8, 2026First studies: 3 phase 2 studiesFirst studyNCT07535931, NCT07534644, NCT07551895

Ahead

  1. Dec 31, 2027Primary completion: phase 2 study in Primary Ovarian InsufficiencyNCT07551895
  2. Dec 31, 2027Primary completion: phase 2 study in Spondylitis, AnkylosingNCT07534644
  3. Dec 31, 2027Primary completion: phase 2 study in Scleroderma, SystemicNCT07535931

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07551895Primary Ovarian Insufficiency2Not yet recruitingDec 31, 202721
NCT07534644Spondylitis, Ankylosing2Not yet recruitingDec 31, 202718
NCT07535931Scleroderma, Systemic2Not yet recruitingDec 31, 202721

How it is read

Names in the registry

  • “HS_SW01 cells injection”, 7 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.